About: Thrombosis centres and AVKs monitoring in COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thrombosis centres and AVKs monitoring in COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Thrombosis centres and AVKs monitoring in COVID-19 pandemic
Creator	Barcellona, Doris Marongiu, Francesco
Source	Medline; PMC
abstract	Vitamin K-Antagonists (VKAs) are the treatment of choice in patients with indications other than atrial fibrillation and venous thromboembolism. Moreover, some patients still assume VKAs refusing to change their therapy when direct oral anticoagulants (DOACs) are properly indicated. The COVID-19 pandemic has completely changed our lives, nullifying inter-personal relationships to avoid contagion, making difficult the VKAs monitoring. We describe the re-organization of our thrombosis centre (TC) as an example on how to face the emergency due to the COVID-19 pandemic. In the first phase, to avoid overcrowding at the TC, we planned to increase the interval time between INRs checks and to encourage blood sampling at home, especially for elderly patients. Moreover, precise scheduled blood sampling was also organized while telephone and email counselling were guaranteed by two doctors of the TC. In the second phase, to reduce the number of patients who daily attended our TC a switch from VKAs to DOACs was carried out, if no contraindications were identified. In the third phase, to protect patients, healthcare staff and hospital from COVID-19 widespread, telemedicine was strengthened. We tried to extend self-testing at home by means of portable coagulometers to as more patients as possible. To avoid patients staying or coming back to the TC an ad hoc web platform for sending the therapeutic dose adjustment and the next scheduled appointment was developed. The TC re-organization allowed us to monitor anticoagulated patients respecting personal isolation and security measures to avoid possible COVID-19 contagion.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1007/s11739-020-02439-4
bibo:pmid	32686059
has license	no-cc
sha1sum (hex)	1666e6a0365af3a3a38438c15c0e799dc6d664bd
schema:url	https://doi.org/10.1007/s11739-020-02439-4
resource representing a document's title	Thrombosis centres and AVKs monitoring in COVID-19 pandemic
has PubMed Central identifier	PMC7369471
has PubMed identifier	32686059
schema:publication	Intern Emerg Med
resource representing a document's body	covid:1666e6a0365af3a3a38438c15c0e799dc6d664bd#body_text
is schema:about of	named entity 'pandemic' named entity 'hospital' named entity 'time' named entity 'TO REDUCE' named entity 'ANTAGONISTS' named entity 'DIFFICULT' named entity 'EXAMPLE' named entity 'coming' named entity 'emergency' named entity 'anticoagulated' named entity 'COVID-19' named entity 'portable' named entity 'patients' named entity 'pandemic' named entity 'patients' named entity 'monitor' named entity 'healthcare' named entity 'counselling' named entity 'venous thromboembolism' named entity 'reduce' named entity 'properly' named entity 'phase' named entity 'centres' named entity 'telemedicine' named entity 'blood sampling' named entity 'COVID-19 pandemic' named entity 'DOACs' named entity 'healthcare staff' named entity 'inter-personal relationships' named entity 'DOACs' named entity 'therapeutic dose' named entity 'atrial fibrillation' named entity 'INRs' named entity 'elderly patients' named entity 'COVID-19 pandemic' named entity 'ad hoc' named entity 'March 11' named entity 'anticoagulation' named entity 'therapeutic range' named entity 'cardiovascular' named entity 'COVID-19 infection' named entity 'cardiovascular disease' named entity 'blood sampling' named entity 'infection' named entity 'telemedicine' named entity 'anticoagulated' named entity 'blood sampling' named entity 'informed consent' named entity 'fever' named entity 'telemedicine' named entity 'COVID' named entity 'leave home' named entity 'oral anticoagulants' named entity 'Thrombosis' named entity 'lyophilized' named entity 'Italy' named entity 'prothrombin time' named entity 'Antithrombotic' named entity 'overdose' named entity 'INR' named entity 'Bolzano' named entity 'clinical history' named entity 'INR' named entity 'risks and benefits' named entity 'Oral anticoagulants' named entity 'COVID' named entity 'questionnaire' named entity 'Italy' named entity 'DOACs' named entity 'quality of life' named entity 'elderly patients' named entity 'INR' named entity 'COVID-19' named entity 'elderly patients' named entity 'COVID-19' named entity 'obesity' named entity 'thromboembolic events' named entity 'questionnaire' named entity 'inter-personal relationships' named entity 'DOACs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software